Study of two drugs for extensive-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two drugs (valemetostat and atezolizumab) for people with extensive-stage small cell lung cancer who have already responded to initial chemo-immunotherapy. The goal is to see if adding valemetostat can keep the cancer from growing longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with extensive-stage small cell lung cancer.
- You have completed 4 cycles of initial treatment with a platinum-based chemotherapy plus atezolizumab (an immunotherapy).
- After that initial treatment, your cancer has not grown (stable disease), or has shrunk (partial or complete response).
- You are able to start this new treatment within 4 weeks of finishing your fourth cycle.
- You have not had radiation to the chest after your initial therapy.
- Your overall health is good enough to participate (able to care for yourself, no uncontrolled infections or heart problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (BL-M14D1 and Atezolizumab) for people with extensive-stage small cell lung cancer that has not responded to standard treatments. The goal is to see if the combination can shrink tumors or slow the growth of the cancer.
This trial tests a new combination of immunotherapy (adebrelimab), a targeted drug (famitinib), and standard chemotherapy for people with extensive stage small cell lung cancer who have not had treatment before. The goal is to see if this combination works better than chemotherapy alone.
This trial tests an investigational drug called BNT327, given with standard chemotherapy, for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to see if adding this drug improves outcomes compared to chemotherapy alone.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This trial tests adding a new drug, iadademstat, to standard immunotherapy drugs (atezolizumab or durvalumab) for people with small cell lung cancer that responded to initial treatment. The goal is to see if this combination works better at preventing cancer from returning.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.